Medicare AdvantageCoverageMedium impact
MA07.008e, Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions
Independence Blue Cross·Orthopedics, Wound Care, Sports Medicine +1 more·Medical Policy
Effective date
Jan 6, 2025
We identified it
Jun 19, 2026
Summary
A fresh Medicare Advantage policy update has been issued for stem-cell therapy/platelet-rich plasma treatments in orthopedic applications and wound healing conditions. This policy change affects coverage positions and reimbursement guidelines for these specialized treatments, potentially impacting billing procedures for practices offering regenerative medicine services.
Action Required
Immediately: Billing team must review the updated MA07.008e policy for stem-cell therapy and platelet-rich plasma treatments. Verify current coverage criteria and reimbursement guidelines for Medicare Advantage plans. Update billing procedures and prior authorization requirements as specified in the new policy to ensure compliant claims submission.